研究者総覧

釜田 康行 (カマタ ヤスユキ)

  • 内科学講座(アレルギー膠原病学部門) 講師
Last Updated :2022/09/17

研究者情報

ホームページURL

J-Global ID

研究分野

  • ライフサイエンス / 膠原病、アレルギー内科学

所属学協会

  • 日本肺循環学会   日本内科学会   日本臨床免疫学会   日本アレルギー学会   日本リウマチ学会   

研究活動情報

論文

  • Yasuyuki Kamata, Seiji Minota
    RHEUMATOLOGY INTERNATIONAL 35 9 1607 - 1608 2015年09月 [査読有り][通常論文]
  • Yasuyuki Kamata, Seiji Minota
    EUROPEAN JOURNAL OF INTERNAL MEDICINE 26 5 371 - 372 2015年06月 [査読有り][通常論文]
  • Yasuyuki Kamata, Seiji Minota
    RHEUMATOLOGY INTERNATIONAL 34 11 1623 - 1626 2014年11月 [査読有り][通常論文]
     
    Raynaud's phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP. Three patients with mixed connective tissue disease and three patients with systemic sclerosis having RP were enrolled. Oral sildenafil, vardenafil, or tadalafil was administered. The fingertip temperature was measured by thermography before and 120 min after administration. To evaluate longer effects, vardenafil was administered daily for 12 weeks; the fingertip temperature was measured by thermography before and 12 weeks after administration. As compared with the pre-administration of sildenafil, vardenafil, and tadalafil, the mean fingertip temperature increased by 2.17, 3.47, and 3.59 A degrees C, respectively, in 120 min. In the 12-week trial with vardenafil in 3 patients, the mean fingertip temperature increased by 3.04, 7.96, and 3.32 A degrees C from baseline in each patient. PDE-5Is significantly increased fingertip temperature within 120 min, and the effect of vardenafil lasted for 12 weeks under daily use. PDE-5Is were safe and would be an effective treatment for RP with CTDs.
  • Yasuyuki Kamata, Seiji Minota
    Rheumatology (United Kingdom) 52 6 1008  2013年06月 [査読有り][通常論文]
  • Akihito Maruyama, Takao Nagashima, Yasuyuki Kamata, Katsuya Nagatani, Takamasa Murosaki, Taku Yoshio, Seiji Minota
    Rheumatology International 33 1 267 - 268 2013年01月 [査読有り][通常論文]
  • Masahiro Iwamoto, Sumiko Homma, Sachiko Onishi, Yasuyuki Kamata, Katsuya Nagatani, Zentaro Yamagata, Seiji Minota
    RHEUMATOLOGY INTERNATIONAL 32 11 3691 - 3694 2012年11月 [査読有り][通常論文]
     
    We examined change in the antibody titre against pandemic influenza A/H1N1/2009 before and after vaccination in Japanese patients with rheumatoid arthritis. This observational study was conducted with the participation of five hospitals in Japan. A total of 89 patients with rheumatoid arthritis were included in this study. The seroprotection and seroresponse rates to vaccination with the pandemic influenza A/H1N1/2009 vaccine were analysed. The seroprotection rates prior to the vaccination were 5.6% in the Japanese patients with rheumatoid arthritis. The seroprotection rates after subcutaneous vaccination were 55.1%. The seroresponse rate after subcutaneous vaccination was 50.6% in the patients with rheumatoid arthritis. Both the seroprotection and seroresponse rates obtained after the vaccination with the pandemic influenza A/H1N1/2009 vaccine were low in Japanese patients with rheumatoid arthritis. We should realise that a vaccination against this newly emerged influenza virus may protect only half of the Japanese patients with rheumatoid arthritis in a real world.
  • Nagashima T, Okazaki H, Kamata Y, Minota S
    Modern rheumatology / the Japan Rheumatism Association 22 4 638 - 639 4 2012年08月 [査読有り][通常論文]
  • Takao Nagashima, Akihito Maruyama, Yasuyuki Kamata, Seiji Minota
    RHEUMATOLOGY INTERNATIONAL 32 7 2231 - 2232 2012年07月 [査読有り][通常論文]
  • Matsuyama Y, Okazaki H, Hoshino M, Onishi S, Kamata Y, Nagatani K, Nagashima T, Iwamoto M, Yoshio T, Ohto-Ozaki H, Tamemoto H, Komine M, Sekiya H, Tominaga S, Minota S
    Rheumatology international 32 5 1397 - 1401 5 2012年05月 [査読有り][通常論文]
     
    Although TNF inhibitors have dramatically improved the outcome of patients with rheumatoid arthritis, 30-40% of patients do not respond well to them and treatment needs to be changed. In an effort to discriminate good and poor responders, we focused on the change in serum and synovial fluid levels of interleukin (IL-) 33 before and after treatment with TNF inhibitors. They were also measured in synovial fluids from 17 TNF inhibitor-na < ve patients, and fibroblast-like synoviocytes (FLS) in-culture from 6 patients and correlated with various pro-inflammatory cytokines. Serum levels of IL-33 at 6 months after treatment decreased significantly in responders, while they did not change in non-responders. Synovial fluid levels of IL-33 in 6 patients under treatment with TNF inhibitors stayed high in 3 who were refractory and slightly elevated in 2 moderate responders, while they were undetectable in one patient under remission. Among inflammatory cytokines measured in 17 synovial fluids from TNF inhibitor-na < ve patients, levels of IL-33 showed a significant positive correlation only to those of IL-1 beta. IL-1 beta increased IL-33 expression markedly in FLS in vitro, compared to TNF-alpha. IL-1 beta might be inducing RA inflammation through producing pro-inflammatory IL-33 in TNF inhibitor-hypo-responders. Sustained elevation of serum and/or synovial levels of IL-33 may account for a poor response to TNF inhibitors, although how TNF inhibitors affect the level of IL-33 remains to be elucidated.
  • Masahiro Iwamoto, Takeshi Kamimura, Takao Nagashima, Yasuyuki Kamata, Yoko Aoki, Sachiko Onishi, Seiji Minota
    RHEUMATOLOGY INTERNATIONAL 32 3 801 - 804 2012年03月 [査読有り][通常論文]
     
    Prospective observational study was performed to elucidate the incidence and characteristics of healthcare-associated infections in a university hospital for rheumatology care. In this study, a total of 1,226 patients were prospectively enrolled between March 2004 and February 2006 and between April 2008 and December 2008. Healthcare-associated infection was defined as an infection developing after the third day of admission to the rheumatology ward. We detected the following 54 healthcare-associated infections in 49 patients: respiratory tract infection, 14 cases; Clostridium difficile infection, 2 cases; urinary tract infection, 4 cases; bloodstream infection, 9 cases; skin infection, 2 cases; reactivation of latent cytomegalovirus infection, 6 cases; herpes zoster infection, 5 cases; Candida infection, 7 cases; others, 4 cases. The incidence rate of respiratory tract infection was the highest. Methicillin-resistant Staphylococcus aureus was the causative bacterium in 21% of respiratory tract infections cases. Bloodstream infection due to the insertion of a catheter and opportunistic infection by a latent virus were also occurred commonly. Respiratory tract infection, bloodstream infection and opportunistic infection by a latent virus were the most common causes of healthcare-associated infection in rheumatology. It is important to pay more attention to healthcare-associated infection.
  • Yasuyuki Kamata, Seiji Minota
    INTERNAL MEDICINE 51 6 687 - 688 2012年 [査読有り][通常論文]
  • Yasuyuki Kamata, Seiji Minota
    BMJ Case Reports 2012 2012年 [査読有り][通常論文]
     
    A 51-year-old Japanese woman developed systemic lupus erythematosus (SLE) in 1995. In August 2005, she had massive pericardial effusion due to lupus pericarditis, which was compromising her circulation. Methylprednisolone pulse, intravenous cyclophosphamide pulse and pericardiocentesis were all ineffective. The pericardium was cut surgically to create a passage to drain the liquid into the pleural cavity. The procedure was temporarily effective however, massive liquid accumulated in the pleural cavity within 1 year. Oral tacrolimus and topical betamethasone injection were ineffective. Since the interleukin-6 (IL-6) level in the effusion was markedly increased (1160 pg/ml), tocilizumab was administered intravenously at a dose of 8 mg/kg every 4 weeks. The effect was astonishing and only a residual amount of pericardial effusion remained. Prednisolone was tapered successfully from 15 to 5 mg daily. Tocilizumab is a treatment of choice when we confront an intractable serositis with massive effusion in SLE, if the IL-6 level is high. Copyright 2012 BMJ Publishing Group. All rights reserved.
  • Multiple Arterial Microaneurysms in Polyarteritis Nodosa
    Kamata Y, Seiji M
    BMJ 343 d6854  2011年10月 [査読有り][通常論文]
  • Yasuyuki Kamata, Masahiro Iwamoto, Kazuo Muroi, Seiji Minota
    RHEUMATOLOGY 50 5 906 - 910 2011年05月 [査読有り][通常論文]
     
    Methods. Three patients with SSc, two with microscopic polyangiitis and one with MCTD were enrolled. All patients had severe RP, ulcers and/or necrosis in the extremities. MNCs were obtained from 400 to 1600 ml of peripheral blood and implanted into 20-80 different sites in the palms and/or soles. This procedure was repeated every 3 months up to 1 year. Humoral factors were measured by ELISAs. Results. Visual analogue scale scores for pain, coldness and subjective satisfaction were improved after implantation in all patients. Pre-treatment ulcers in five patients were cured after repeated implantations. Angiography showed increased vasculature compared with baseline. Serum levels of VEGF increased after implantation, whereas levels of IL-1 beta, fibroblast growth factor and endostatin had variable results. None of the patients had any adverse reactions during a follow-up period of up to 3 years. Conclusions. Repeated implantation of peripheral blood MNCs was effective and safe for the treatment of recalcitrant ulcers developing in ischaemic digits and toes in patients with CTD.
  • Matsuyama Y, Nagashima T, Honne K, Kamata Y, Iwamoto M, Okazaki H, Sato K, Ozawa K, Minota S
    Internal medicine 50 6 639 - 642 6 2011年 [査読有り][通常論文]
     
    A 63-year-old woman receiving tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) was found to have smoldering IgA-kappa type multiple myeloma (MM). Retrospective examination of stored serum samples revealed a steady increase of serum IgA levels after the start of TNF inhibitor therapy. The patient's articular symptoms showed marked exacerbation when TNF inhibitors were discontinued because of fear of worsening the MM. Tocilizumab improved RA symptoms dramatically and stabilized serum IgA levels for 13 months after a transient steep rise. This case suggests that tocilizumab can be used safely in patients with inflammatory disorders with coexisting MM.
  • Yasushi Matsuyama, Hitoaki Okazaki, Hiroyuki Tamemoto, Hirotaka Kimura, Yasuyuki Kamata, Katsuya Nagatani, Takao Nagashima, Morisada Hayakawa, Masahiro Iwamoto, Taku Yoshio, Shin-Ichi Tominaga, Seiji Minota
    JOURNAL OF RHEUMATOLOGY 37 1 18 - 25 2010年01月 [査読有り][通常論文]
     
    Objective. To determine levels of interleukin 33 (IL-33) in serum and synovial fluid (SF) and their clinical associations in patients with rheumatoid arthritis (RA). To evaluate the ability of activated peripheral blood mononuclear cells (PBMC) and fibroblast-like synoviocytes (FLS) from RA patients to release IL-33. Methods. Sera were obtained from 59 patients with RA, 10 patients with infectious diseases, and 42 healthy volunteers. SF samples were obtained from 15 patients with RA and 13 with osteoarthritis. IL-33 levels were measured using a sandwich ELISA after removal of rheumatoid factor with protein A-Sepharose beads. FLS were stimulated with IL-1 beta and tumor necrosis factor, and treated with or without chemical damage. PBMC were stimulated with anti-CD3/CD28 antibodies. The levels of IL-33 were measured in the culture supernatants and cell lysates by ELISA or immunoblotting. Results. Serum IL-33 levels were significantly higher in RA patients, especially in the high disease activity group compared to the moderate or low activity group. IL-33 levels in SF were elevated in all 15 RA patients measured. IL-33 levels were higher in SF samples than in sera in 7 RA patients measured simultaneously. The 30-kDa IL-33 precursor was detected in the culture supernatants of damaged FLS but was not detected in those of activated PBMC and non-damaged FLS. Conclusion. IL-33 levels were elevated in sera and SF samples from patients with RA, and correlated with disease activity. IL-33 was produced mainly in inflamed joints; IL-33/ST2L signaling might play an important role in joint inflammation of human RA. (First Release Nov 15 2009; J Rheumatol 2010;37;18-25; doi:10.3899/jrheum.090492)
  • Shino Takatori, Yasuyuki Kamata, Takamasa Murosaki, Masahiro Iwamoto, Seiji Minota
    JOURNAL OF RHEUMATOLOGY 37 1 210 - 212 2010年01月 [査読有り][通常論文]
  • Yoko Aoki, Masahiro Iwamoto, Yasuyuki Kamata, Takao Nagashima, Taku Yoshio, Hitoaki Okazaki, Seiji Minota
    RHEUMATOLOGY INTERNATIONAL 29 11 1327 - 1330 2009年09月 [査読有り][通常論文]
     
    The objective of this study is to investigate the clinical markers of life-threatening Pneumocystis pneumonia (PCP) in patients with collagen vascular diseases (CVD). The patients who contracted Pneumocystis jeroveccii were retrospectively selected from our medical charts and conditions related to the patients' death were reviewed. The findings indicated that lower levels of serum albumin and cholinesterase, increased alveolar-arterial oxygen gradient, intratracheal intubation, and necessity to treat in the intensive care unit were significantly related to deaths associated with PCP in CVD. A special attention should be paid to decreased serum albumin and cholinesterase as ominous predictors in PCP occurred in patients with CVD.
  • Takao Nagashima, Sachiko Onishi, Yasuyuki Kamata, Seiji Minota
    RHEUMATOLOGY INTERNATIONAL 29 10 1261 - 1262 2009年08月 [査読有り][通常論文]
  • Kamata Y, Iwamoto M, Minota S
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 15 213  4 2009年06月 [査読有り][通常論文]
  • Kamata Y, Iwamoto M, Minota S
    Japanese journal of clinical immunology 31 6 424 - 431 6 2008年12月 [査読有り][通常論文]
     
    肺高血圧症は,稀な疾患ではあるが進行性かつ難治性で治療に難渋する.膠原病でもしばしば肺高血圧症の合併を認めるが,その予後は極めて不良である.しかし,近年プロスタサイクリンであるエポプロステノールをはじめ,エンドセリン受容体拮抗薬であるボセンタンや,ホスホジエステラーゼ-5阻害薬であるシルデナフィルなど,強力な血管拡張作用を有する薬剤が本邦でも使用できるようになった.これらの薬剤は運動耐容能をはじめ,循環動態,ADLの改善,さらには肺高血圧症の予後の改善が大いに期待できる薬剤である.本稿では肺高血圧症の治療薬のうち,最近本邦で認可されたエンドセリン受容体拮抗薬とホスホジエステラーゼ-5阻害薬について解説する.
  • S. Onishi, K. Ikenoya, K. Matsumoto, Y. Kamata, T. Nagashima, T. Kamimura, M. Iwamoto, S. Minota
    RHEUMATOLOGY 47 11 1730 - 1732 2008年11月 [査読有り][通常論文]
  • Takao Nagashima, Hikaru Okubo-Fornbacher, Yoko Aoki, Yasuyuki Kamata, Hirotaka Kimura, Takeshi Kamimura, Hiroyuki Nara, Masahiro Iwamoto, Taku Yoshio, Hitoaki Okazaki, Seiji Minota
    JOURNAL OF RHEUMATOLOGY 35 5 936 - 938 2008年05月 [査読有り][通常論文]
  • Y. Kamata, M. Iwamoto, Y. Aoki, Y. Kishaba, T. Nagashima, H. Nara, T. Kamimura, A. Tanaka, T. Yoshio, H. Okazaki, S. Minota
    LUPUS 17 11 1033 - 1035 2008年 [査読有り][通常論文]
     
    Systemic lupus erythematosus (SLE) is often complicated by pericarditis with effusion, which generally responds well to glucocorticoid. We report herein a Japanese patient with SLE who showed a sign of cardiac tamponade and severe chest and back pain because of massive intractable pericardial effusion. Pulse glucocorticoid and pulse cyclophosphamide gained marginal effects. Pericardial effusion accumulated again soon after ultrasound-guided pericardiocentesis and drainage. Pericardial fenestration performed Surgically as a last resort, for draining pericardial fluid into the pleural space, was very effective, and only a much smaller amount of fluid was observed in the space thereafter in comparison with the volume before the surgery. Pathological examination of the retrieved pericardium unfolded intense hyperplasia of small vessels and capillaries. Levels of IL-6 and TNF-alpha in pericardial effusion were extremely higher than those in serum. Pericardial effusion with extensive capillary hyperplasia in SLE would be resistant to medical treatment and require surgical fenestration. Lupus (2008) 17, 1033-1035.
  • Kamata Y, Takahashi Y, Iwamoto M, Matsui K, Murakami Y, Muroi K, Ikeda U, Shimada K, Yoshio T, Okazaki H, Minota S
    Rheumatology (Oxford, England) 46 882 - 884 5 2007年05月 [査読有り][通常論文]
  • Y. Kamata, M. Iwamoto, S. Minota
    LUPUS 16 11 901 - 903 2007年 [査読有り][通常論文]
     
    Sildenafil and bosentan were added recently to the treatment with great expectations, effectiveness for the acute exacerbation of pulmonary arterial hypertension (PAH) is not fully examined. Two cases of acutely exacerbated PAH associated with collagen vascular diseases were treated first with sildenafil for six months followed by bosentan for another six months and the characteristics of this treatment modality were examined. Sildenafil showed an immediate effect which started in as early as similar to 30 min and was maximized in 60-90 min after oral ingestion. Continuous use of sildenafil for six months lowered pulmonary arterial pressure, pulmonary vascular resistance and the levels of brain natriuretic peptides along with an increased distance in 6-minute-walk, and replacement of it to with bosentan kept these effects. We think it as a treatment choice to use sildenafil first as a reliever and replace it with a controller bosentan, considering the immediate effects of sildenafil.
  • Kamata Y, Iwamoto M, Aoki Y, Nagashima T, Nara H, Kamimura T, Yoshio T, Okazaki H, Minota S
    Jichi Medical University journal 29 163 - 167 自治医科大学 2006年12月 [査読有り][通常論文]
     
    2005年1月から6月までにアレルギーリウマチ科に入院した100症例を対象とし,入院時と入院1週間後に血中Dダイマー値を測定した。Dダイマーレベルが高値またはその変化が大きかった症例と,下肢深部静脈血栓症(DVT)を疑わせる症状を有する症例について下肢静脈超音波検査を行い,DVTの有無を検査した。その結果,100例中5例にDVTを認めた。うち3例は入院前からDVTを発症しており,2例は入院中に新たにDVTを発症した。DVTがみつかった5症例は全例臨床症状を伴っていたが,臨床症状を伴っていてもDダイマーレベルが上昇していない症例は,下肢静脈超音波検査にてDVTは見られなかった。Dダイマーレベルの変化と臨床症状が見られた症例に対して下肢静脈超音波検査を行うことにより,効率的にDVTを診断できるものと考えられた。
  • Kamata Y, Iwamoto M, Nara H, Kamimura T, Takayashiki N, Yamamoto H, Sugano K, Yoshio T, Okazaki H, Minota S
    Gut 55 1372  9 2006年09月 [査読有り][通常論文]
  • Y. Kamata, M. Iwamoto, T. Kamimura, E. Kanashiki, T. Yoshio, H. Okazaki, T. Morita, S. Minota
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY 16 6 388 - 390 2006年 [査読有り][通常論文]
     
    A 70-year-old man presenting with a chief complaint of tongue swelling had been diagnosed with prostate cancer 1 year earlier. He had been on an oral angiotensin-converting enzyme inhibitor (ACE) inhibitor for hypertension for 20 years. Two months before the first of 4 episodes of tongue swelling within a period of 40 days, he had been prescribed oral estramustine phosphate (EMP) for the prostate cancer. He was admitted to our hospital for the evaluation after massive swelling of the tongue and epiglottis which necessitated tracheotomy. Food allergies, allergic reactions to environmental factors, and hereditary angioneurotic edema were excluded. Massive swelling of the tongue and epiglottis disappeared completely after EMP was discontinued. We concluded that angioedema was induced by EMP used concurrently with the ACE inhibitor.
  • Y Kamata, H Nara, H Sato, JI Masuyama, S Minota, T Yoshio
    ANNALS OF THE RHEUMATIC DISEASES 64 8 1236 - 1237 2005年08月 [査読有り][通常論文]
  • Y Kamata, T Kamimura, M Iwamoto, S Minota
    CLINICAL AND EXPERIMENTAL DERMATOLOGY 30 4 451 - 451 2005年07月 [査読有り][通常論文]
  • Y Kamata, T Kamimura, K Haneda, J Masuyama, H Okazaki, S Minota
    LUPUS 14 8 641 - 642 2005年 [査読有り][通常論文]
  • Y Kamata, H Nara, T Kamimura, K Haneda, M Iwamoto, J Masuyama, HI Okazayi, S Minota
    INTERNAL MEDICINE 43 12 1201 - 1204 2004年12月 [査読有り][通常論文]
     
    A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide. Because all bacteriology findings were negative, steroid pulse-therapy was initiated promptly due to the rapidity of chest X-ray progression and the deterioration of arterial blood oxygen pressure. Although cough was induced by methotrexate, interstitial pneumonia was not detected clinically before leflunomide administration. He finally died of respiratory failure 128 days after the onset of acute interstitial pneumonia. According to the post-market surveillance, as high as similar to1.1% of the patients on leflunomide have developed interstitial pneumonia in Japan. It is important to emphasize that acute interstitial pneumonia due to leflunomide is a very severe and potentially fatal side effect.
  • Kamata Y, Nagashima T, Muroi K, Yamamoto C, Mori M, Miyazato A, Takatoku M, Nagai T, Otsuki T, Komatsu N, Ozawa K
    Jichi Medical School journal 26 9 - 13 自治医科大学 2003年12月 [査読有り][通常論文]
     
    CatovskyスコアもしくはEGIL(The European Group for the immunological classification of leukemia)スコアによる診断基準を満たしたbiphenotypic acute leukemia(BAL)を8例経験し,臨床的特徴と治療について検討を行った。BALの頻度は急性白血病の6.4%(8/124例),年齢中央値41歳,男女比は1:1。Ph染色体陽性を2例に認めた。ALLに準じた治療を受けた6例中5例が寛解を得,1例が早期再発をした。AMLに準じた治療では2例中2例が寛解を得たが,どちらも早期再発した。寛解後療法として4例が造血幹細胞移植を受け,3例が長期生存している。ALLに準じた化学療法と,寛解後に造血幹細胞移植を受けた患者で,成績が良かった。寛解到達後の造血幹細胞移植が長期生存を期待しうる治療であると考えられた。
  • Kamata Y, Kamimura T, Yoshio T, Hirata D, Masuyama J, Isoda N, Kanai N, Minota S
    Ryumachi. [Rheumatism] 43 667 - 671 4 2003年10月 [査読有り][通常論文]


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.